QureTech Bio granted two US patents strengthening its antibacterial portfolio

February 10, 2026

QureTech Bio AB (“QureTech”) today announced that two of its patent applications have been granted by the United States Patent and Trademark Office (USPTO).

QureTech was granted two U.S. patents by the USPTO—US 12,472,168 on November 18, 2025, and US 12,503,476 on December 23, 2025— both focused on GmPcides, a new class of antibiotics targeting multidrug resistant Gram-positive bacteria.

Contact
Markus Thor, CEO
E-mail:  markus.thor@quretech.com
Telephone: +46 70 644 99 91
Web: www.quretech.com

About QureTech Bio

QureTech Bio AB is a biotechnology company focused on the development of novel therapeutics targeting infectious diseases and cancer. The company’s primary focus is the discovery and development of small‑molecule therapeutics directed at bacterial proteins implicated in cancer, as well as compounds effective against antibiotic‑resistant bacterial strains. QureTech Bio is located in Umeå, Sweden

QureTech Bio granted two US patents strengthening its antibacterial portfolio